http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2769841-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff3e741d8c3082a79ba472a5a4c2bef8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-143333 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6844 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6806 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6813 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2008-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_591871304283c9931b41c2dcf3b3b434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb2f725fad7837aaa30eec4f06f4a4ef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba2d6c3e21155c682eb967249378b51e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c29260e47681adb364af9f65cdbe475b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b6f518560a3593b53495297b9d78fb5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2c7190ddfd736ef3050d22817388390 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6b3bb9a83c47b561c713b9421a6ddc0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f1513adbc8ae6457357676a8f84028c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83907e2bf2e14642e8ffb8ba90828878 |
| publicationDate | 2020-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2769841-T3 |
| titleOfInvention | Methylation analysis method |
| abstract | A method for methylation analysis comprises a) treating genomic DNA with one or more reagents to convert unmethylated cytosine bases to uracil sulfonate or to another base having a different binding behavior from cytosine, while the methylated cytosine remains unchanged ; b) amplifying the treated DNA by means of i) at least one oligonucleotide comprising or consisting of a sequence selected from a group consisting of (1) SEQ ID NO: 6, 48, 62-64 and its variants, (2 ) SEQ ID NO: 6, 44-48 and its variants, (3) SEQ ID NO: 1, 12-15 and its variants, or (4) SEQ ID NO: 92, wherein said at least one oligonucleotide is suitable for its use as a direct primer; and ii) at least one oligonucleotide comprising or consisting of a sequence selected from a group consisting of (1) SEQ ID NO: 65-72 and its variants, (2) SEQ ID NO: 5, 43 and its variants, (3) SEQ ID NO: 2, 16-22, or (4) SEQ ID NO: 1, 12-15 and its variants, wherein said at least one oligonucleotide is suitable for use as a reverse primer; and iii) optionally, at least one oligonucleotide comprising or consisting of a sequence selected from the group consisting of (1) SEQ ID NO: 7, 49, 50, 55-57, 73-76 and its variants, (2) SEQ ID NO: 7, 49-57 and its variants, (3) SEQ ID NO: 3, 9, 23-30 and its variants, or (4) SEQ ID NO: 9, 23, 24, 91, its variants, and 97-101, wherein said at least one oligonucleotide is suitable for use as a blocker; and iv) optionally, at least one oligonucleotide comprising or consisting of a sequence selected from the group consisting of (1) SEQ ID NO: 83, 84 and its variants, (2) SEQ ID NO: 8, 58-61 and its variants, (3) SEQ ID NO: 4, 31-42, and its variants, or (4) SEQ ID NO: 4, 31-42 and its variants, wherein said at least one oligonucleotide is suitable for use as probe; and / or at least one oligonucleotide combination comprising or consisting of any of the sequences of (1) SEQ ID NO: 77 and 78 or their variants, SEQ ID NO: 79 and 80 or their variants, or SEQ ID NO: 81 and 82 or its variants, or (4) SEQ ID NO: 102 and 103, or SEQ ID NO: 104 and 105, wherein said one or more combinations of oligonucleotides are suitable for use as probe combinations, wherein the oligonucleotides (i) to (iv) are selected from one of (1) to (4), and wherein the variants have a 5'-terminal and / or 3'-terminal deletion of 1, 2, 3, 4 or 5 nucleotides; and v) optionally, a polymerase, preferably a thermostable polymerase; c) deduce the presence or absence of methylation of the CpG dinucleotides amplified in step b) from the results of step b). |
| priorityDate | 2007-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 346.